{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:44:07Z","timestamp":1790664247214,"version":"4.1.0"},"reference-count":274,"publisher":"National Institute for Health and Care Research","issue":"43","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["14\/27\/02"],"award-info":[{"award-number":["14\/27\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title><jats:p>Antipsychotic medication can cause tardive dyskinesia (TD) \u2013 late-onset, involuntary, repetitive movements, often involving the face and tongue. TD occurs in &gt;\u200920% of adults taking antipsychotic medication (first-generation antipsychotics for &gt;\u20093 months), with this proportion increasing by 5% per year among those who continue to use these drugs. The incidence of TD among those taking newer antipsychotics is not different from the rate in people who have used older-generation drugs in moderate doses. Studies of TD have previously been found to be limited, with no treatment approach shown to be effective.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-2\"><jats:title>Objectives<\/jats:title><jats:p>To summarise the clinical effectiveness and safety of treatments for TD by updating past Cochrane reviews with new evidence and improved methods; to undertake public consultation to gauge the importance of the topic for people living with TD\/the risk of TD; and to make available all data from relevant trials.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-3\"><jats:title>Data sources<\/jats:title><jats:p>All relevant randomised controlled trials (RCTs) and observational studies.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-4\"><jats:title>Review methods<\/jats:title><jats:p>Cochrane review methods, network meta-analysis (NMA).<\/jats:p><\/jats:sec><jats:sec id=\"abs1-5\"><jats:title>Design<\/jats:title><jats:p>Systematic reviews, patient and public involvement consultation and NMA.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-6\"><jats:title>Setting<\/jats:title><jats:p>Any setting, inpatient or outpatient.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-7\"><jats:title>Participants<\/jats:title><jats:p>For systematic reviews, adults with TD who have been taking a stable antipsychotic drug dose for &gt;\u20093 months.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-8\"><jats:title>Interventions<\/jats:title><jats:p>Any, with emphasis on those relevant to UK NHS practice.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-9\"><jats:title>Main outcome measures<\/jats:title><jats:p>Any measure of TD, global assessments and adverse effects\/events.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-10\"><jats:title>Results<\/jats:title><jats:p>We included 112 studies (nine Cochrane reviews). Overall, risk of bias showed little sign of improvement over two decades. Taking the outcome of \u2018TD symptoms improved to a clinically important extent\u2019, we identified two trials investigating reduction of antipsychotic dose [<jats:italic>n<\/jats:italic>\u2009=\u200917, risk ratio (RR) 0.42, 95% confidence interval (CI) 0.17 to 1.04; very low quality]. Switching was investigated twice in trials that could not be combined (switching to risperidone vs. antipsychotic withdrawal: one RCT,<jats:italic>n<\/jats:italic>\u2009=\u200942, RR 0.45, 95% CI 0.23 to 0.89; low quality; switching to quetiapine vs. haloperidol: one RCT,<jats:italic>n<\/jats:italic>\u2009=\u200945, RR 0.80, 95% CI 0.52 to 1.22; low quality). In addition to RCTs, six observational studies compared antipsychotic discontinuation with decreased or increased dosage, and there was no clear evidence that any of these strategies had a beneficial effect on TD symptoms (very low-quality evidence). We evaluated the addition to standard antipsychotic care of several treatments, but not anticholinergic treatments, for which we identified no trials. We found no clear effect of the addition of either benzodiazepines (two RCTs,<jats:italic>n<\/jats:italic>\u2009=\u200932, RR 1.12, 95% CI 0.6 to 2.09; very low quality) or vitamin E (six RCTs,<jats:italic>n<\/jats:italic>\u2009=\u2009264, RR 0.95, 95% CI 0.89 to 1.01; low quality). Buspirone as an adjunctive treatment did have some effect in one small study (<jats:italic>n<\/jats:italic>\u2009=\u200942, RR 0.53, 95% CI 0.33 to 0.84; low quality), as did hypnosis and relaxation (one RCT,<jats:italic>n<\/jats:italic>\u2009=\u200915, RR 0.45, 95% CI 0.21 to 0.94; very low quality). We identified no studies focusing on TD in people with dementia. The NMA model found indirect estimates to be imprecise and failed to produce useful summaries on relative effects of interventions or interpretable results for decision-making. Consultation with people with\/at risk of TD highlighted that management of TD remains a concern, and found that people are deeply disappointed at the length of time it has taken researchers to address the issue.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-11\"><jats:title>Limitations<\/jats:title><jats:p>Most studies remain small and poorly reported.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-12\"><jats:title>Conclusions<\/jats:title><jats:p>Clinicians, policy-makers and people with\/at risk of TD are little better informed than they were decades ago. Underpowered trials of limited quality repeatedly fail to provide answers.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-13\"><jats:title>Future work<\/jats:title><jats:p>TD reviews have data from current trials extracted, tabulated and traceable to source. The NMA highlights one context in which support for this technique is ill advised. All relevant trials, even if not primarily addressing the issue of TD, should report appropriate binary outcomes on groups of people with this problem. Randomised trials of treatments for people with established TD are indicated. These should be large (&gt;\u2009800 participants), necessitating accrual through accurate local\/national registers, including an intervention with acceptable treatments and recording outcomes used in clinical practice.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-14\"><jats:title>Study registration<\/jats:title><jats:p>This study is registered as PROSPERO CRD4201502045.<\/jats:p><\/jats:sec><jats:sec id=\"abs1-15\"><jats:title>Funding<\/jats:title><jats:p>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta21430","type":"journal-article","created":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T10:00:16Z","timestamp":1502877616000},"page":"1-218","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia"],"prefix":"10.3310","volume":"21","author":[{"given":"Hanna","family":"Bergman","sequence":"first","affiliation":[{"name":"Cochrane Response, Cochrane, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn-Marie","family":"Walker","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriani","family":"Nikolakopoulou","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventative Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Soares-Weiser","sequence":"additional","affiliation":[{"name":"Cochrane Editorial Unit and Cochrane Innovations, Cochrane, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive E","family":"Adams","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2017,8]]},"reference":[{"key":"key20170815152846577_ref1-bib1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handb Clin Neurol"},{"key":"key20170815152846577_ref1-bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1192\/bjp.bp.106.035063","article-title":"Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics","volume":"191","author":"Rosenheck","year":"2007","journal-title":"Br J Psychiatry"},{"key":"key20170815152846577_ref1-bib3","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4088\/JCP.v68n1210","article-title":"Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis","volume":"68","author":"Miller","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib4","volume-title":"Psychopharmacology: 4th Generation of Progress","author":"Kane","year":"1995"},{"key":"key20170815152846577_ref1-bib5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1017\/S204579601300019X","article-title":"Predicting the incidence of antipsychotic-induced movement disorders in long-stay patients: a prospective study","volume":"22","author":"Bakker","year":"2013","journal-title":"Epidemiol Psychiatr Sci"},{"key":"key20170815152846577_ref1-bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0920-9964(14)70282-8","article-title":"Antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study","volume":"153","author":"Bakker","year":"2014","journal-title":"Schizophr Res"},{"key":"key20170815152846577_ref1-bib7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"Br J Psychiatry"},{"key":"key20170815152846577_ref1-bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib9","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/npp.2011.55","article-title":"Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-na\u00efve patients","volume":"36","author":"Woerner","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"key20170815152846577_ref1-bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive dyskinesia: therapeutic options for an increasingly common disorder","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"key":"key20170815152846577_ref1-bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18553\/jmcp.2012.18.S5-B.1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics","volume":"18","author":"Maher","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"key20170815152846577_ref1-bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-200004000-00011","article-title":"Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies","volume":"20","author":"Ballesteros","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib13","first-page":"44","article-title":"Prevalence of tardive dyskinesia and all-cause mortality amongst patients in a large psychiatric institute in Rio de Janeiro","volume":"38","author":"Martins","year":"2011","journal-title":"Rev Psiquiatr Clin"},{"key":"key20170815152846577_ref1-bib14","volume-title":"Psychosis and Schizophrenia in Adults: Treatment and Management. NICE Clinical Guideline 178","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key20170815152846577_ref1-bib15","doi-asserted-by":"crossref","DOI":"10.3109\/9780203092835","volume-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2009","edition":"10th edn."},{"key":"key20170815152846577_ref1-bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000298255","article-title":"Introduction","volume":"168","author":"Lieberman","year":"1996","journal-title":"Br J Psychiatry"},{"key":"key20170815152846577_ref1-bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychother Psychosom"},{"key":"key20170815152846577_ref1-bib18","doi-asserted-by":"publisher","first-page":"CD000459","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","volume":"1","author":"Soares-Weiser","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib19","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1176\/appi.ajp.2007.07071150","article-title":"Chronic restlessness with antipsychotics","volume":"164","author":"Bratti","year":"2007","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib20","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/mds.26014","article-title":"Current therapeutic options for Huntington\u2019s disease: good clinical practice versus evidence-based approaches?","volume":"29","author":"Killoran","year":"2014","journal-title":"Mov Disord"},{"key":"key20170815152846577_ref1-bib21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/bmj.319.7210.623","article-title":"Acute dystonia induced by drug treatment","volume":"319","author":"van Harten","year":"1999","journal-title":"BMJ"},{"key":"key20170815152846577_ref1-bib22","first-page":"CD006456","article-title":"Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease","volume":"3","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib23","first-page":"CD000458","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia","volume":"1","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0006-3223(93)90044-E","article-title":"Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia","volume":"34","author":"Miller","year":"1993","journal-title":"Bio Psychiatry"},{"key":"key20170815152846577_ref1-bib25","first-page":"231","volume-title":"Antipsychotic Drugs and their Side-Effects","author":"Barnes","year":"1993"},{"key":"key20170815152846577_ref1-bib26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/309347a0","article-title":"Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis","volume":"309","author":"Gunne","year":"1984","journal-title":"Nature"},{"key":"key20170815152846577_ref1-bib27","volume-title":"Psychopharmacology The Fourth Generation of Progress","author":"Gardos","year":"1994"},{"key":"key20170815152846577_ref1-bib28","volume-title":"Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association","author":"American Psychiatric Association Task Force on Tardive Dyskinesia","year":"1992"},{"key":"key20170815152846577_ref1-bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00004714-198808001-00008","article-title":"Pharmacological treatments of tardive dyskinesia in the 1980s","volume":"8","author":"Jeste","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib30","first-page":"CD001950","article-title":"Benzodiazepines for neuroleptic-induced acute akathisia","volume":"1","author":"Lima","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0952-3278(96)90149-0","article-title":"Antioxidant treatment of tardive dyskinesia","volume":"55","author":"Rotrosen","year":"1996","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"key20170815152846577_ref1-bib32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E","volume":"570","author":"Cadet","year":"1989","journal-title":"Ann N Y Acad Sci"},{"key":"key20170815152846577_ref1-bib33","first-page":"25","article-title":"Progress in the treatment of tardive dyskinesia: theory and practice","volume":"44","author":"Feltner","year":"1993","journal-title":"Hosp Community Psychiatry"},{"key":"key20170815152846577_ref1-bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/schbul\/19.2.303","article-title":"Tardive dyskinesia","volume":"19","author":"Jeste","year":"1993","journal-title":"Schizophr Bull"},{"key":"key20170815152846577_ref1-bib35","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0278-5846(99)00074-3","article-title":"Effects of buspirone on an animal model of tardive dyskinesia","volume":"23","author":"Queiroz","year":"1999","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pbb.2007.04.007","article-title":"Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats","volume":"87","author":"Haleem","year":"2007","journal-title":"Pharmacol Biochem Behav"},{"key":"key20170815152846577_ref1-bib37","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1212\/01.wnl.0000314667.16386.5e","article-title":"Mind-body interventions: applications in neurology","volume":"70","author":"Wahbeh","year":"2008","journal-title":"Neurology"},{"key":"key20170815152846577_ref1-bib38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ctim.2014.03.013","article-title":"Effectiveness of autogenic training in improving motor performances in Parkinson\u2019s disease","volume":"22","author":"Ajimsha","year":"2014","journal-title":"Complement Ther Med"},{"key":"key20170815152846577_ref1-bib39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.psc.2010.04.013","article-title":"Behavioral interventions for tic disorders","volume":"33","author":"Franklin","year":"2010","journal-title":"Psychiatr Clin North Am"},{"key":"key20170815152846577_ref1-bib40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/00207144.2013.753829","article-title":"Feasibility of clinical hypnosis for the treatment of Parkinson\u2019s disease: a case study","volume":"61","author":"Elkins","year":"2013","journal-title":"Int J Clin Exp Hypn"},{"key":"key20170815152846577_ref1-bib41","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/bmj.316.7131.631a","article-title":"Writing to authors of systematic reviews elicited further data in 17% of cases","volume":"316","author":"McGrath","year":"1998","journal-title":"BMJ"},{"key":"key20170815152846577_ref1-bib42","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(96)91525-1","article-title":"Evidence and tardive dyskinesia","volume":"347","author":"Soares","year":"1996","journal-title":"Lancet"},{"key":"key20170815152846577_ref1-bib43","doi-asserted-by":"publisher","first-page":"CD000203","DOI":"10.1002\/14651858.CD000203.pub3","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","volume":"4","author":"Alabed","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib44","doi-asserted-by":"publisher","first-page":"CD000205","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","volume":"3","author":"Bhoopathi","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib45","doi-asserted-by":"publisher","first-page":"CD000206","DOI":"10.1002\/14651858.CD000206.pub3","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","volume":"11","author":"Essali","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib46","first-page":"CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","volume":"2","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib47","doi-asserted-by":"publisher","first-page":"CD000209","DOI":"10.1002\/14651858.CD000209.pub2","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","volume":"2","author":"Soares-Weiser","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib48","first-page":"CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","volume":"2","author":"Soares-Weiser","year":"1997","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib49","first-page":"CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","volume":"3","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"key20170815152846577_ref1-bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(99)00021-3","article-title":"The treatment of tardive dyskinesia \u2013 a systematic review and meta-analysis","volume":"39","author":"Soares","year":"1999","journal-title":"Schizophr Res"},{"key":"key20170815152846577_ref1-bib51","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2147\/DDDT.S32328","article-title":"New and emerging treatments for symptomatic tardive dyskinesia","volume":"7","author":"Rana","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"key20170815152846577_ref1-bib52","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Ann Intern Med"},{"key":"key20170815152846577_ref1-bib53","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"2011"},{"key":"key20170815152846577_ref1-bib54","volume-title":"Appendix: Traceable Extracted Data from Included Studies of Tardive Dyskinesia Reviews","author":"Adamd","year":"2016"},{"key":"key20170815152846577_ref1-bib55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"key20170815152846577_ref1-bib56","first-page":"233","article-title":"The Extrapyramidal Symptom Rating Scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"key20170815152846577_ref1-bib57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"key20170815152846577_ref1-bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"key20170815152846577_ref1-bib59","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jrsm.1056","article-title":"Issues relating to study design and risk of bias when including non-randomized studies in systematic reviews on the effects of interventions","volume":"4","author":"Higgins","year":"2013","journal-title":"Res Synth Methods"},{"key":"key20170815152846577_ref1-bib60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"Br J Psychiatry"},{"key":"key20170815152846577_ref1-bib61","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"Int J Epidemiol"},{"key":"key20170815152846577_ref1-bib62","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key20170815152846577_ref1-bib63","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat Med"},{"key":"key20170815152846577_ref1-bib64","first-page":"295","volume-title":"The Handbook of Research Synthesis and Meta-Analysis","author":"Raudenbush","year":"2009"},{"key":"key20170815152846577_ref1-bib65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/sim.2514","article-title":"Confidence intervals for the amount of heterogeneity in meta-analysis","volume":"26","author":"Viechtbauer","year":"2007","journal-title":"Stat Med"},{"key":"key20170815152846577_ref1-bib66","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"key20170815152846577_ref1-bib67","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"key20170815152846577_ref1-bib68","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jclinepi.2013.02.004","article-title":"The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses","volume":"66","author":"Mustafa","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"key20170815152846577_ref1-bib69","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1002\/sim.2704","article-title":"Evidence-based sample size calculations based upon updated meta-analysis","volume":"26","author":"Sutton","year":"2007","journal-title":"Stat Med"},{"key":"key20170815152846577_ref1-bib70","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jclinepi.2011.10.009","article-title":"Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis","volume":"65","author":"Langan","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"key20170815152846577_ref1-bib71","first-page":"281","article-title":"A controlled study on the treatment of tardive dyskinesia using 1-stepholidine","volume":"21","author":"Cai","year":"1988","journal-title":"Zhonghua Shen Jing Jing Shen Ke Za Zhi"},{"key":"key20170815152846577_ref1-bib72","first-page":"203","article-title":"A double-blind auto-control study on the effect of bromocriptine on tardive dyskinesia","volume":"4","author":"Chen","year":"1995","journal-title":"Chin J Pharmacoepidemiol"},{"key":"key20170815152846577_ref1-bib73","first-page":"304","article-title":"\u03b3-aminobutyric acid in the treatment of 20 cases of tardive dyskinesia","volume":"27","author":"Mei","year":"2008","journal-title":"Herald Med"},{"key":"key20170815152846577_ref1-bib74","first-page":"391","article-title":"Melatonin in treatment of schizophrenia with tardive dyskinesia: a comparison study of cognitive function","volume":"19","author":"Shi","year":"2009","journal-title":"Linchuang Jingshen Yixue Zazhi"},{"key":"key20170815152846577_ref1-bib75","first-page":"17","article-title":"Clonazepam therapy of tardive dyskinesia: a double-blind trial","volume":"12","author":"Xiang","year":"1997","journal-title":"West China Med J"},{"key":"key20170815152846577_ref1-bib76","first-page":"365","article-title":"Promethazine treatment of tardive dyskinesia: a double blind placebo controlled study","volume":"13","author":"Yang","year":"1999","journal-title":"Chin Ment Health J"},{"key":"key20170815152846577_ref1-bib77","first-page":"92","article-title":"A double-blind comparative study of sodium valproate in treating of TD","volume":"14","author":"Yin","year":"2004","journal-title":"J Clin Psychol Med"},{"key":"key20170815152846577_ref1-bib78","first-page":"202","article-title":"Treatment of tardive dyskinesia with buspirone","volume":"7","author":"Zeng","year":"1995","journal-title":"Med J Chinese Civil Admin"},{"key":"key20170815152846577_ref1-bib79","first-page":"240","article-title":"Pemoline in the treatment of tardive dyskinesia","volume":"15","author":"Zeng","year":"1996","journal-title":"Chin J New Drugs Clin Remedies"},{"key":"key20170815152846577_ref1-bib80","first-page":"183","article-title":"A double-blind trial of flunarizine therapy for tardive dyskinesia","volume":"3","author":"Zeng","year":"1994","journal-title":"Chin J Pharmaco Epidemiol"},{"key":"key20170815152846577_ref1-bib81","first-page":"388","article-title":"Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics","volume":"98","author":"Hebenstreit","year":"1986","journal-title":"Wien Klin Wochenschr"},{"key":"key20170815152846577_ref1-bib82","first-page":"103","article-title":"Treatment with dimethylaminoethanol (deanol) in neuroleptic induced tardive dyskinesia","volume":"126","author":"Kocher","year":"1980","journal-title":"Schweiz Arch Neurol Neurochir Psychiatr"},{"key":"key20170815152846577_ref1-bib83","unstructured":"Lucius G. Uber die Therapeutische Wirksamkeit von Dimethylaminoaethanol bei Neuroleptikainduzierten Sp\u00e4thyperkinesen. Dissertation. Freiburg im Breisgau: Albert Ludwigs University of Freiburg; 1978."},{"key":"key20170815152846577_ref1-bib84","first-page":"627","article-title":"A double-blind clinical trial of dihydrogenated ergot alkaloids in antipsychotic-induced tardive dyskinesia","volume":"25","author":"Koshino","year":"1983","journal-title":"Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib85","first-page":"421","article-title":"Double-blind trial of cyproheptadine on neuroleptic induced tardive dyskinesia","volume":"21","author":"Koshino","year":"1979","journal-title":"Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib86","first-page":"455","article-title":"Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia \u2013 a double-blind placebo-controlled study","volume":"18","author":"Yagi","year":"1990","journal-title":"Rinsho Hyoka"},{"key":"key20170815152846577_ref1-bib87","first-page":"29","article-title":"The effectiveness of rivastigmine in reducing tardive dyskinesia symptoms in patients with schizophrenia","volume":"20","author":"Jahanian","year":"2014","journal-title":"Iran J Psychiatry Clin Psychol"},{"key":"key20170815152846577_ref1-bib88","first-page":"261","article-title":"A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia","volume":"29","author":"Karniol","year":"1983","journal-title":"Acta Psiquiatr Psicol Am Lat"},{"key":"key20170815152846577_ref1-bib89","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/106002808301700705","article-title":"Diazepam in tardive dyskinesia","volume":"17","author":"Weber","year":"1983","journal-title":"Drug Intell Clin Pharm"},{"key":"key20170815152846577_ref1-bib90","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0006-3223(96)00367-8","article-title":"Treatment of long-term tardive dyskinesia with vitamin E","volume":"41","author":"Dorevitch","year":"1997","journal-title":"Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib91","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004850-199705000-00008","article-title":"Lack of effect of vitamin E on serum creatine phosphokinase in patients with long-term tardive dyskinesia","volume":"12","author":"Dorevitch","year":"1997","journal-title":"Int Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib92","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1176\/ajp.149.6.773","article-title":"Treatment of tardive dyskinesia with vitamin E","volume":"149","author":"Egan","year":"1992","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib93","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1176\/ajp.147.4.505","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"147","author":"Elkashef","year":"1990","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib94","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005053-199402000-00009","article-title":"Vitamin E in the treatment of tardive dyskinesia: a replication study","volume":"182","author":"Lam","year":"1994","journal-title":"J Nerv Ment Dis"},{"key":"key20170815152846577_ref1-bib95","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S0924933800002625","article-title":"Treatment of tardive dyskinesias with vitamin E","volume":"6","author":"Schmidt","year":"1991","journal-title":"Eur Psychiatry"},{"key":"key20170815152846577_ref1-bib96","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib97","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archpsyc.1983.01790070083010","article-title":"Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates","volume":"40","author":"Kane","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"key20170815152846577_ref1-bib98","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-198704000-00008","article-title":"The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime","volume":"2","author":"Cookson","year":"1987","journal-title":"Int Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0006-3223(92)90579-O","article-title":"The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients","volume":"31","author":"Chouinard","year":"1992","journal-title":"Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib100","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00002826-199202001-00514","article-title":"Antidyskinetic effect of risperidone in chronic schizophrenic patients","volume":"15","author":"Chouinard","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"key20170815152846577_ref1-bib101","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00004714-199502001-00007","article-title":"Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study","volume":"15","author":"Chouinard","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib102","unstructured":"Chouinard G. Arnott W. An Antidyskinetic Effect of Risperidone. Proceedings of the 9th World Congress of Psychiatry, Rio de Janeiro, 6\u201312 June, 1993."},{"key":"key20170815152846577_ref1-bib103","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib104","first-page":"102","article-title":"Clozapine in tardive dyskinesia: observations from human and animal model studies","volume":"55","author":"Tamminga","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib105","first-page":"S165","article-title":"Risperidone for severe tardive dyskinesia: one year follow up study","volume":"5","author":"Bai","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"key20170815152846577_ref1-bib106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00004850-200503000-00003","article-title":"Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study","volume":"20","author":"Bai","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib107","unstructured":"Pai YM, Yu SC, Lin CC. Risperidone in Reducing Tardive Dyskinesia: A Double-Blind, Placebo-Controlled Study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, 18\u201323 May 2002."},{"key":"key20170815152846577_ref1-bib108","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.4088\/JCP.v64n1110","article-title":"Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study","volume":"64","author":"Bai","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib109","unstructured":"Pai YM, Yu SC, Lin CC. Risperidone in Reducing Tardive Dyskinesia: A Double-Blind, Placebo-Controlled Study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, 5\u201310 May 2001."},{"key":"key20170815152846577_ref1-bib110","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.v65n0516","article-title":"A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia","volume":"65","author":"Emsley","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib111","unstructured":"Emsley RA, Turner J, Schronen J, Botha K, Smit R, Oosthuizen PP. Quetiapine: Greater Improvements in Tardive Dyskinesia versus Haloperidol. 157th Annual Meeting of the American Psychiatric Association, New York, NY, 1\u20136 May 2004."},{"key":"key20170815152846577_ref1-bib112","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0924-977X(05)80979-4","article-title":"Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study","volume":"15","author":"Bai","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"key20170815152846577_ref1-bib113","doi-asserted-by":"crossref","unstructured":"Bai YM, Ping LY, Lin CC, Wang YC, Liou YL, Wu BJ, et al. Comparative Effects of Atypical Antipsychotic on Tardive Dyskinesia and Neurocognition: A 24-week Randomized, Single-Blind, Controlled Study. Proceedings of the 8th World Congress of Psychiatry, Cairo, Egypt, 10\u201315 September 2005.","DOI":"10.1016\/S0924-977X(05)80979-4"},{"key":"key20170815152846577_ref1-bib114","volume-title":"Tardive Dyskinesia and Cognitive Function","author":"Bai","year":"2008"},{"key":"key20170815152846577_ref1-bib115","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.09m05155yel","article-title":"A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia","volume":"71","author":"Chan","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib116","volume-title":"Risperidone and Olanzapine for the Schizophrenic Patients with Neuroleptic-Induced Tardive Dyskinesia","author":"NCT00621998","year":"2008"},{"key":"key20170815152846577_ref1-bib117","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4088\/JCP.09m05793yel","article-title":"Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia","volume":"72","author":"Caroff","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib118","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","article-title":"Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial","volume":"80","author":"Miller","year":"2005","journal-title":"Schizophr Res"},{"key":"key20170815152846577_ref1-bib119","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1192\/bjp.145.3.304","article-title":"Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study","volume":"145","author":"Greil","year":"1984","journal-title":"Br J Psychiatry"},{"key":"key20170815152846577_ref1-bib120","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1176\/ajp.138.2.189","article-title":"Clonazepam and phenobarbital in tardive dyskinesia","volume":"138","author":"Bobruff","year":"1981","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib121","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archpsyc.1988.01800310063008","article-title":"Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms","volume":"45","author":"Csernansky","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"key20170815152846577_ref1-bib122","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00004714-198804000-00028","article-title":"The effect of benzodiazepines on tardive dyskinesia symptoms","volume":"8","author":"Csernansky","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib123","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0006-3223(97)00027-9","article-title":"Long-term treatment effects of vitamin E for tardive dyskinesia","volume":"43","author":"Adler","year":"1998","journal-title":"Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib124","unstructured":"Adler LA, Peselow E, Angrist B, Duncan E, Lee M, Rosenthal M, et al. Vitamin E in Tardive Dyskinesia: Effects of Longer Term Treatment. Proceedings of the 31st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 14\u201318 December 1992."},{"key":"key20170815152846577_ref1-bib125","first-page":"371","article-title":"Vitamin E in tardive dyskinesia: time course of effect after placebo substitution","volume":"29","author":"Adler","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"key20170815152846577_ref1-bib126","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","article-title":"Vitamin E treatment of tardive dyskinesia","volume":"150","author":"Adler","year":"1993","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib127","first-page":"124","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"39","author":"Akhtar","year":"1993","journal-title":"J Postgrad Med"},{"key":"key20170815152846577_ref1-bib128","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1176\/ajp.151.6.925","article-title":"Effectiveness of vitamin E for treatment of long-term tardive dyskinesia","volume":"151","author":"Dabiri","year":"1994","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib129","first-page":"167","article-title":"A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia","volume":"57","author":"Lohr","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004850-199807000-00001","article-title":"Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses","volume":"13","author":"Sajjad","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib131","first-page":"53","article-title":"Interrater reliability issues in multicentric trials, part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study 394","volume":"33","author":"Tracy","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"key20170815152846577_ref1-bib132","first-page":"861","article-title":"Whither vitamin E and tardive dyskinesia?","volume":"43","author":"Lohr","year":"1998","journal-title":"Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib133","first-page":"59","article-title":"Interrater reliability issues in multicentric trials, part II: statistical procedures used in Department of Veterans Affairs Cooperative Study #394","volume":"33","author":"Edson","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"key20170815152846577_ref1-bib134","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002130050320","article-title":"Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study #394","volume":"132","author":"Caligiuri","year":"1997","journal-title":"Psychopharmacology"},{"key":"key20170815152846577_ref1-bib135","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/0006-3223(94)91073-1","article-title":"Vitamin E treatment of TD: development of a VA cooperative study","volume":"35","author":"Adler","year":"1994","journal-title":"Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib136","first-page":"809","article-title":"Vitamin E is ineffective in treatment of late dyskinesias","volume":"90","author":"Bridler","year":"2001","journal-title":"Praxis"},{"key":"key20170815152846577_ref1-bib137","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archpsyc.56.9.836","article-title":"Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group","volume":"56","author":"Adler","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"key20170815152846577_ref1-bib138","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/01.jcp.0000104912.75206.2b","article-title":"The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial","volume":"24","author":"Zhang","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib139","unstructured":"Glover O. Alternative Treatment Modalities for Drug Induced Psychomotor Dysfunctions. PhD thesis. Berkeley, CA: The Wright Institute;1980."},{"key":"key20170815152846577_ref1-bib140","first-page":"130","article-title":"A clinical research of dexetimide and benzhexol for treatment of drug-induced tremor","volume":"15","author":"Zeng","year":"1996","journal-title":"Herald Med"},{"key":"key20170815152846577_ref1-bib141","first-page":"311","article-title":"Vitamin E in the management of drug induced tardive dyskinesia: a double-blind randomized clinical trial","volume":"4","author":"Kar-Ahmadi","year":"2002","journal-title":"J Res Med Sci"},{"key":"key20170815152846577_ref1-bib142","first-page":"91","article-title":"Double-blind placebo controlled study using buspirone in the treatment of tardive dyskinesia","volume":"27","author":"Garcia","year":"1992","journal-title":"ASHP Midyear Clin Meet"},{"key":"key20170815152846577_ref1-bib143","volume-title":"A Six Month, Rater Blind Comparison of Quetiapine and Risperidone in the Treatment of Tardive Dyskinesia in Patients with Schizophrenia","author":"Reynolds","year":"2002"},{"key":"key20170815152846577_ref1-bib144","volume-title":"Investigation of the Potential Beneficial Effects of Cannabidiol in the Treatment of Tardive Dyskinesia","author":"Kajero","year":"2015"},{"key":"key20170815152846577_ref1-bib145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000408484","article-title":"Neuroleptic treatment in tardive dyskinesia: can it be developed into a clinical strategy for long-term treatment?","volume":"21","author":"Casey","year":"1983","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"key20170815152846577_ref1-bib146","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archpsyc.64.2.170","article-title":"Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia","volume":"64","author":"Damier","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"key20170815152846577_ref1-bib147","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1212\/WNL.0000000000002370","article-title":"Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia","volume":"86","author":"Pouclet-Courtemanche","year":"2016","journal-title":"Neurology"},{"key":"key20170815152846577_ref1-bib148","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-0327(02)00043-5","article-title":"Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up","volume":"75","author":"Hardoy","year":"2003","journal-title":"J Affect Disord"},{"key":"key20170815152846577_ref1-bib149","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0165-1781(86)90128-9","article-title":"Comparison of two groups of tardive dyskinesia patients","volume":"19","author":"Huang","year":"1986","journal-title":"Psychiatry Res"},{"key":"key20170815152846577_ref1-bib150","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00002826-199112000-00006","article-title":"A long-term outcome study of tardive dyskinesia in patients on antipsychotic medication","volume":"14","author":"Koshino","year":"1991","journal-title":"Clin Neuropharmacol"},{"key":"key20170815152846577_ref1-bib151","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/10401238909149978","article-title":"Changes in tardive dyskinesia after fluphenazine decanoate discontinuation","volume":"1","author":"Peselow","year":"1989","journal-title":"Ann Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib152","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2302\/kjm.34.211","article-title":"A 10-year follow-up study of tardive dyskinesia \u2013 with special reference to the influence of neuroleptic administration on the long-term prognosis","volume":"34","author":"Yagi","year":"1985","journal-title":"Keio J Med"},{"key":"key20170815152846577_ref1-bib153","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-0447.1992.tb03264.x","article-title":"A 10-year follow-up study of tardive dyskinesia","volume":"86","author":"Yassa","year":"1992","journal-title":"Acta Psychiatr Scand"},{"key":"key20170815152846577_ref1-bib154","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0033-3182(84)72946-X","article-title":"Tardive dyskinesia: a two-year follow-up study","volume":"25","author":"Yassa","year":"1984","journal-title":"Psychosomatics"},{"key":"key20170815152846577_ref1-bib155","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"key":"key20170815152846577_ref1-bib156","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"key":"key20170815152846577_ref1-bib157","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jrsm.34","article-title":"Linear inference for mixed treatment comparison meta-analysis: A two-stage approach","volume":"2","author":"Lu","year":"2011","journal-title":"Res Synth Methods"},{"key":"key20170815152846577_ref1-bib158","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat Med"},{"key":"key20170815152846577_ref1-bib159","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"key":"key20170815152846577_ref1-bib160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/rssa.12010","article-title":"Treatment comparisons for decision making: facing the problems of sparse and few data","volume":"177","author":"Soares","year":"2014","journal-title":"J R Stat Soc Ser A"},{"key":"key20170815152846577_ref1-bib161","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/sim.3511","article-title":"Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells","volume":"28","author":"R\u00fccker","year":"2009","journal-title":"Stat Med"},{"key":"key20170815152846577_ref1-bib162","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/sim.6383","article-title":"Statistical methods for meta-analyses including information from studies without any events-add nothing to nothing and succeed nevertheless","volume":"34","author":"Kuss","year":"2015","journal-title":"Stat Med"},{"key":"key20170815152846577_ref1-bib163","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1471-2288-12-64","article-title":"Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended event","volume":"12","author":"Warren","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"key20170815152846577_ref1-bib164","volume-title":"The Crossover Study. The Design and Analysis of Clinical Experiments","author":"Fleiss","year":"1984"},{"key":"key20170815152846577_ref1-bib165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1991.tb05604.x","article-title":"Should we cross off the crossover?","volume":"32","author":"Armitage","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"key20170815152846577_ref1-bib166","volume-title":"Crossover Trials. Clinical Trials A Practical Approach","author":"Pocock","year":"1983"},{"key":"key20170815152846577_ref1-bib167","doi-asserted-by":"publisher","first-page":"e5913","DOI":"10.1136\/bmj.e5913","article-title":"When is a further clinical trial justified?","volume":"345","author":"Ferreira","year":"2012","journal-title":"BMJ"},{"key":"key20170815152846577_ref1-bib168","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1371\/journal.pmed.0010035","article-title":"Doing new research? Don\u2019t forget the old","volume":"1","author":"Clarke","year":"2004","journal-title":"PLOS Med"},{"key":"key20170815152846577_ref1-bib169","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archpsyc.1972.01750250086012","article-title":"Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"key20170815152846577_ref1-bib170","volume-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2011"},{"key":"key20170815152846577_ref1-bib171","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"key20170815152846577_ref1-bib172","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"key20170815152846577_ref1-bib173","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/9780470712184.ch3","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"key20170815152846577_ref1-bib174","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"key":"key20170815152846577_ref1-bib175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"key20170815152846577_ref1-bib176","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"key":"key20170815152846577_ref1-bib177","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"key":"key20170815152846577_ref1-bib178","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Stat Med"},{"key":"key20170815152846577_ref1-bib179","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2008"},{"key":"key20170815152846577_ref1-bib180","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLOS ONE"},{"key":"key20170815152846577_ref1-bib181","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int J Epidemiol"},{"key":"key20170815152846577_ref1-bib182","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jclinepi.2014.08.012","article-title":"Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data","volume":"68","author":"Rhodes","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"key20170815152846577_ref1-bib183","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"key20170815152846577_ref1-bib184","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"key20170815152846577_ref1-bib185","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A design-by-treatment interaction model for network meta-analysis with random inconsistency effects","volume":"33","author":"Jackson","year":"2014","journal-title":"Stat Med"},{"key":"key20170815152846577_ref1-bib186","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/2046-4053-2-107","article-title":"Risk of bias: a simulation study of power to detect study-level moderator effects in meta-analysis","volume":"2","author":"Hempel","year":"2013","journal-title":"Syst Rev"},{"key":"key20170815152846577_ref1-bib187","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Res Synth Methods"},{"key":"key20170815152846577_ref1-bib188","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0924-977X(91)90008-I","article-title":"Zuclopenthixol, a combined dopamine D1\/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia","volume":"1","author":"Lublin","year":"1991","journal-title":"Eur Neuropsychopharmacol"},{"key":"key20170815152846577_ref1-bib189","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0920-9964(90)90016-Z","article-title":"A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia","volume":"3","author":"Glazer","year":"1990","journal-title":"Schizophr Res"},{"key":"key20170815152846577_ref1-bib190","first-page":"4","article-title":"Molindone and haloperidol in tardive dyskinesia","volume":"46","author":"Glazer","year":"1985","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib191","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-IV","author":"American Psychiatric Association","year":"2000"},{"key":"key20170815152846577_ref1-bib192","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archpsyc.1982.04290040080014","article-title":"Research diagnoses for tardive dyskinesia","volume":"39","author":"Schooler","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"key20170815152846577_ref1-bib193","volume-title":"DSM-IIl-R: Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987","edition":"3rd edn"},{"key":"key20170815152846577_ref1-bib194","volume-title":"Classification of Diseases and Injuries","author":"National Center for Health Statistics","year":"2002"},{"key":"key20170815152846577_ref1-bib195","volume-title":"Chinese Classification of Mental Disorders, Second Edition, Revised (CCMD-2-R)","author":"Chinese Medical Association and Nanjing Medical University","year":"1995"},{"key":"key20170815152846577_ref1-bib196","volume-title":"The Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization"},{"key":"key20170815152846577_ref1-bib197","first-page":"324","article-title":"The dyskenesias: a new therapeutic approach","volume":"32","author":"Bucci","year":"1971","journal-title":"Dis Nerv Syst"},{"key":"key20170815152846577_ref1-bib198","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00004714-199202000-00007","article-title":"Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial","volume":"12","author":"Loonen","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib199","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0920-9964(97)82352-3","article-title":"Effect of nifedipine on motor skill learning in schizophrenia","volume":"24","author":"Schwartz","year":"1997","journal-title":"Schizophr Res"},{"key":"key20170815152846577_ref1-bib200","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00002826-199708000-00009","article-title":"Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia","volume":"20","author":"Schwartz","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"key20170815152846577_ref1-bib201","unstructured":"Beckham BJ. Lecithin Therapy for Tardive Dyskinesia. Dissertation. Denton, TX: North Texas State University; 1981."},{"key":"key20170815152846577_ref1-bib202","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4088\/JCP.v68n0309","article-title":"Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial","volume":"68","author":"Caroff","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib203","volume-title":"Treatment of Tardive Dyskinesia with Galantamine","author":"Caroff","year":"2005"},{"key":"key20170815152846577_ref1-bib204","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00492207","article-title":"Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study","volume":"65","author":"de Montigny","year":"1979","journal-title":"Psychopharmacology"},{"key":"key20170815152846577_ref1-bib205","first-page":"149","article-title":"A crossover study of lecithin treatment of tardive dyskinesia","volume":"51","author":"Gelenberg","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib206","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/00048678109159413","article-title":"Double blind controlled trial of deanol in tardive dyskinesia","volume":"15","author":"George","year":"1981","journal-title":"Aust N Z J Psychiatry"},{"key":"key20170815152846577_ref1-bib207","first-page":"725","article-title":"Cholinergic enhancement in tardive dyskinesia","volume":"24","author":"Jackson","year":"1978","journal-title":"Curr Ther Res Clin Exp"},{"key":"key20170815152846577_ref1-bib208","first-page":"85","article-title":"Lecithin administration in tardive dyskinesia: clinical and biomedical correlates","volume":"16","author":"Jackson","year":"1981","journal-title":"Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib209","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1176\/ajp.136.11.1458","article-title":"Treatment of tardive dyskinesia with lecithin","volume":"136","author":"Jackson","year":"1979","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00369796","article-title":"Deanol in tardive dyskinesia: a double-blind study","volume":"222","author":"Bockenheimer","year":"1976","journal-title":"Arch Psychiatr Nervenkr"},{"key":"key20170815152846577_ref1-bib211","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/JCP.0b013e3181934475","article-title":"Effect of donepezil on tardive dyskinesia","volume":"29","author":"Ogunmefun","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib212","unstructured":"Price LA. Lecithin Treatment for Tardive Dyskinesia: A Clinical Evaluation. Dissertation. Denton, TX: North Texas State University; 1982."},{"key":"key20170815152846577_ref1-bib213","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archneur.1977.00500240044007","article-title":"Deanol acetamidobenzoate treatment in choreiform movement disorders","volume":"34","author":"Tarsy","year":"1977","journal-title":"Arch Neurol"},{"key":"key20170815152846577_ref1-bib214","first-page":"267","article-title":"Experimental design and analysis for determination of improvement rating by video imaging \u2013 a double-blind placebo-controlled study for Meclofenoxate hydrochloride (Lucidril) in tardive dyskinesia","volume":"19","author":"Ojima","year":"1991","journal-title":"Rinsho Hyoka"},{"key":"key20170815152846577_ref1-bib215","unstructured":"Yagi G, Kamizima K, Miura S. Meclofenoxate (Lucidril) in Tardive Dyskinesia \u2013 A Double-Blind Placebo-Controlled Study. Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress, Kyoto, Japan, September 10\u201314 1990."},{"key":"key20170815152846577_ref1-bib216","first-page":"111","article-title":"Baclofen in the treatment of tardive dyskinesia","volume":"42","author":"Ananth","year":"1987","journal-title":"Curr Ther Res Clin Exp"},{"key":"key20170815152846577_ref1-bib217","first-page":"289","article-title":"Preliminary observations on the therapeutic action of progabide in tardive dyskinesia","volume":"2","author":"Burner","year":"1989","journal-title":"Brain Dysfunct"},{"key":"key20170815152846577_ref1-bib218","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1192\/bjp.150.4.542","article-title":"The effect of sodium valproate on tardive dyskinesia \u2013 revisited","volume":"150","author":"Fisk","year":"1987","journal-title":"Br J Psychiatry"},{"key":"key20170815152846577_ref1-bib219","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1176\/ajp.134.7.781","article-title":"The relationship between parkinsonism and tardive dyskinesia","volume":"134","author":"Gerlach","year":"1977","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00431840","article-title":"Effect of baclofen on tardive dyskinesia","volume":"56","author":"Gerlach","year":"1978","journal-title":"Psychopharmacology"},{"key":"key20170815152846577_ref1-bib221","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF00432517","article-title":"The treatment of tardive dyskinesia with baclofen","volume":"87","author":"Glazer","year":"1985","journal-title":"Psychopharmacology"},{"key":"key20170815152846577_ref1-bib222","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1192\/bjp.129.2.114","article-title":"Effect of sodium valproate on tardive dyskinesia","volume":"129","author":"Linnoila","year":"1976","journal-title":"Br J Psychiatry"},{"key":"key20170815152846577_ref1-bib223","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1176\/ajp.135.12.1562","article-title":"Baclofen in the treatment of tardive dyskinesia","volume":"135","author":"Nair","year":"1978","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib224","first-page":"437","article-title":"Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies","volume":"24","author":"Nair","year":"1980","journal-title":"Adv Biochem Psychopharmacol"},{"key":"key20170815152846577_ref1-bib225","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00002826-198212000-00004","article-title":"Baclofen in tardive dyskinesia patients maintained on neuroleptics","volume":"5","author":"Stewart","year":"1982","journal-title":"Clin Neuropharmacol"},{"key":"key20170815152846577_ref1-bib226","first-page":"A114","article-title":"Baclofen for tardive dyskinesia: a double-blind placebo-controlled trial","volume":"32","author":"Stewart","year":"1982","journal-title":"Neurology"},{"key":"key20170815152846577_ref1-bib227","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/archpsyc.1987.01800180032006","article-title":"Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment","volume":"44","author":"Thaker","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"key20170815152846577_ref1-bib228","first-page":"252","article-title":"Effectiveness of melatonin in tardive dyskinesia","volume":"52","author":"Castro","year":"2011","journal-title":"Invest Clin"},{"key":"key20170815152846577_ref1-bib229","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2006.03.023","article-title":"The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial","volume":"84","author":"Emsley","year":"2006","journal-title":"Schizophr Res"},{"key":"key20170815152846577_ref1-bib230","volume-title":"Double-Blind, Randomized, Parallel-Group Comparison of Ethyl-eicosapentaenoic Acid (ethyl-EP A) versus Placebo as add-on Medication in 84 Patients with Established Tardive Dyskinesia","author":"Elmsley","year":"2002"},{"key":"key20170815152846577_ref1-bib231","volume-title":"Ethyl Eicosapentanoic Acid for Tardive Dyskinesia","author":"Emsley","year":"2009"},{"key":"key20170815152846577_ref1-bib232","volume-title":"A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-eicosapentaenoic Acid (ethyl-epa) versus Placebo as add-on Medication in Patients with Established Tardive Dyskinesia","author":"NCT00114595","year":"2005"},{"key":"key20170815152846577_ref1-bib233","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.psychres.2007.06.029","article-title":"Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial","volume":"161","author":"Emsley","year":"2008","journal-title":"Psychiatry Res"},{"key":"key20170815152846577_ref1-bib234","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0364-7722(79)90008-0","article-title":"The effects of papaverine in tardive dyskinesia","volume":"3","author":"Gardos","year":"1979","journal-title":"Prog Neuropsychopharmacol"},{"key":"key20170815152846577_ref1-bib235","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0306-4530(85)90011-3","article-title":"Estrogen replacement and tardive dyskinesia","volume":"10","author":"Glazer","year":"1985","journal-title":"Psychoneuroendocrinology"},{"key":"key20170815152846577_ref1-bib236","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/0006-3223(93)90119-X","article-title":"A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia","volume":"33","author":"Goff","year":"1993","journal-title":"Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib237","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00433006","article-title":"Effect of co-dergocrine mesylate on tardive dyskinesia. A preliminary report","volume":"79","author":"Hajioff","year":"1983","journal-title":"Psychopharmacology"},{"key":"key20170815152846577_ref1-bib238","first-page":"2177","article-title":"Treatment of tardive dyskinesia with ceruletide: a double-blind placebo-controlled study","volume":"44","author":"Kojima","year":"1989","journal-title":"Saishin-Igaku"},{"key":"key20170815152846577_ref1-bib239","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-1781(92)90127-O","article-title":"Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study","volume":"43","author":"Kojima","year":"1992","journal-title":"Psychiatry Res"},{"key":"key20170815152846577_ref1-bib240","volume-title":"Piracetam for Tardive Dyskinesia","author":"Lerner","year":"2009"},{"key":"key20170815152846577_ref1-bib241","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4088\/JCP.v68n0709","article-title":"Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study","volume":"68","author":"Libov","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib242","first-page":"3","article-title":"Piracetam reduces TD symptoms tardive dyskinesia","volume":"18","author":"Anon","year":"2007","journal-title":"Brown Uni Psychopharmacol Update"},{"key":"key20170815152846577_ref1-bib243","author":"NCT00190008","year":"2005","journal-title":"Therapeutic use of Piracetam for Treatment of Patients Suffering from Tardive Dyskinesia \u2013 A Double Blind, Placebo-Controlled Crossover Study"},{"key":"key20170815152846577_ref1-bib244","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S0033291700047498","article-title":"Failure of lithium treatment in established tardive dyskinesia","volume":"10","author":"MacKay","year":"1980","journal-title":"Psychol Med"},{"key":"key20170815152846577_ref1-bib245","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0278-5846(88)90112-1","article-title":"The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study","volume":"12","author":"Matsunaga","year":"1988","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib246","first-page":"884","article-title":"Ritanserin in tardive dyskinesia: a double-blind crossover study versus placebo","volume":"46","author":"Meco","year":"1989","journal-title":"Curr Ther Res Clin Exp"},{"key":"key20170815152846577_ref1-bib247","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0920-9964(95)95640-U","article-title":"Phenylalanine loading effects on tardive dyskinesia severity in schizophrenics","volume":"15","author":"Mosnik","year":"1995","journal-title":"Schizophr Res"},{"key":"key20170815152846577_ref1-bib248","unstructured":"Mosnik DM. Phenylalanine Loading Effects on Tardive Dyskinesia Severity in Schizophrenics. Master of Science dissertation. North Chicago, IL: Finch University of Health Sciences; 1994."},{"key":"key20170815152846577_ref1-bib249","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0893-133X(96)00054-1","article-title":"Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients","volume":"16","author":"Mosnik","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"key20170815152846577_ref1-bib250","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000116678","article-title":"Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture?","volume":"31","author":"Mouret","year":"1991","journal-title":"Eur Neurol"},{"key":"key20170815152846577_ref1-bib251","unstructured":"O\u2019Brien CF, Jimenez R, Hauser RA, Factor SA, Mandri DF, Castro-Gyol JC. Kinect 2: NBI-98854 Treatment of Moderate to Severe Tardive Dyskinesia. 18th International Congress of Parkinson\u2019s Disease and Movement Disorders, Stockholm, Sweden, 2014."},{"key":"key20170815152846577_ref1-bib252","volume-title":"Nbi-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia","author":"NCT01733121","year":"2012"},{"key":"key20170815152846577_ref1-bib253","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S0033291700046778","article-title":"Co-dergocrine (hydergine) in the treatment of tardive dyskinesia","volume":"12","author":"Rastogi","year":"1982","journal-title":"Psychol Med"},{"key":"key20170815152846577_ref1-bib254","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1176\/appi.ajp.160.6.1117","article-title":"Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men","volume":"160","author":"Richardson","year":"2003","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib255","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4088\/JCP.v61n0803","article-title":"Is melatonin treatment effective for tardive dyskinesia?","volume":"61","author":"Shamir","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib256","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archpsyc.58.11.1049","article-title":"Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study","volume":"58","author":"Shamir","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"key20170815152846577_ref1-bib257","doi-asserted-by":"crossref","unstructured":"Shamir EZ, Barak F, Shalman I, et al. Melatonin Treatment for Tardive Dyskinesia: A Double-Blind, Placebo-Controlled, Cross-Over Study. Annual Meeting of the American Psychiatric Association, Los Angeles, CA, USA, 5\u201310 May 2001.","DOI":"10.1001\/archpsyc.58.11.1049"},{"key":"key20170815152846577_ref1-bib258","volume-title":"An 8-week Exploratory, Double-Blind, Placebo Controlled, Randomized Trial \u2013 Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg\/day (250-500 mg Oral Tablets in Bid Administration) on Neuroleptic-Induced Tardive Dyskinesia in Subjects with Stable Axis I Psychiatric Disorder, Aged from at least 18 Years to 80 Years","author":"NCT00175955","year":"2005"},{"key":"key20170815152846577_ref1-bib259","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1176\/ajp.143.7.912","article-title":"Essential fatty acid supplementation in tardive dyskinesia","volume":"143","author":"Wolkin","year":"1986","journal-title":"Am J Psychiatry"},{"key":"key20170815152846577_ref1-bib260","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v69n0405","article-title":"Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Woods","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib261","volume-title":"Levetiracetam Treatment of Tardive Dyskinesia","author":"NCT00291213","year":"2006"},{"key":"key20170815152846577_ref1-bib262","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4088\/JCP.09m05125yel","article-title":"Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Zhang","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"key20170815152846577_ref1-bib263","unstructured":"Zhang F, Bigos K, Weinberger D. Genome-Wide Analysis of Antipsychotic Drug Response in Schizophrenia. Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, HI, USA, 4\u20138 December 2011."},{"key":"key20170815152846577_ref1-bib264","volume-title":"Extract of Ginkgo biloba and Tardive Dyskinesia","author":"Tan","year":"2008"},{"key":"key20170815152846577_ref1-bib265","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0404.1982.tb03059.x","article-title":"Tiapride in the treatment of tardive dyskinesia","volume":"65","author":"Buruma","year":"1982","journal-title":"Acta Neurol Scand"},{"key":"key20170815152846577_ref1-bib266","first-page":"1234","article-title":"Tiapride in Huntington\u2019s chorea and tardive dyskinesia. A double-blind, placebo controlled crossover clinical trial","volume":"7","author":"Roos","year":"1982","journal-title":"J Drug Res"},{"key":"key20170815152846577_ref1-bib267","first-page":"41","article-title":"Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia","volume":"16","author":"Huang","year":"1980","journal-title":"Psychopharmacol Bull"},{"key":"key20170815152846577_ref1-bib268","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00426466","article-title":"Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia","volume":"73","author":"Huang","year":"1981","journal-title":"Psychopharmacology"},{"key":"key20170815152846577_ref1-bib269","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"33","author":"Pappa","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"key20170815152846577_ref1-bib270","first-page":"171","article-title":"Efficacy of amantadine in the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study","author":"Pappa","year":"2009","journal-title":"Biol Psychiatry"},{"key":"key20170815152846577_ref1-bib271","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1016\/S0920-9964(12)71045-9","article-title":"Efficacy of an NMDA receptor antagonist in the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"136","author":"Pappa","year":"2012","journal-title":"Schizophr Res"},{"key":"key20170815152846577_ref1-bib272","first-page":"2195","article-title":"Tiapride treatment of tardive dyskinesia due to long-term neuroleptic treatment","volume":"60","author":"Rust","year":"1984","journal-title":"Sem Hop"},{"key":"key20170815152846577_ref1-bib273","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-198808001-00009","article-title":"Double-blind carbidopa\/levodopa and placebo study in tardive dyskinesia","volume":"8","author":"Simpson","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"key20170815152846577_ref1-bib274","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1600-0447.1986.tb06267.x","article-title":"Oxypertine in tardive dyskinesia: a long-term controlled study","volume":"74","author":"Soni","year":"1986","journal-title":"Acta Psychiatr Scand"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta21430\/hta21430.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002727","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta21430\/hta21430.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2010827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:49:46Z","timestamp":1692114586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta21430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":274,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2017,8]]}},"alternative-id":["10.3310\/hta21430"],"URL":"https:\/\/doi.org\/10.3310\/hta21430","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}